摘要
目的探讨2-巯基-1-甲基咪唑联合骨化三醇对甲亢患者临床疗效的影响。方法纳入东阳市横店集团医院内分泌科确诊的77例甲亢患者,随机分为对照组和实验组,对照组38例患者予常规2-巯基-1-甲基咪唑治疗,实验组39例患者在对照组的基础上予骨化三醇,疗程为6周。比较治疗前后患者的血清三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)、骨密度(BMD)、Barthel指数、疼痛指数的变化及不良事件的发生率。结果治疗后2组患者血清FT3、FT4水平降低,TSH水平增高(P<0.05),治疗后实验组3项指标的水平与对照组比较,差异无统计学意义;治疗后2组BMD和Barthel指数明显提高,疼痛指数降低(P<0.05),治疗后实验组BMD和Barthel指数均高于对照组(P<0.05),疼痛指数低于对照组(P<0.05)。治疗后实验组的不良反应反生率与对照组比较,差异无统计学意义。结论甲亢患者应用骨化三醇对甲状腺激素水平无影响,但能改善甲亢性骨质疏松相关症状。
Objective To investigate the effect of methimazole combined with calcitriol on clinical therapeutic in treatment of patients with hyperthyroidism. Methods 77 cases with hyperthyroidism were divided into 2 groups,control group was treated with methimazole,experimental group was treated on the basis of control group with calcitriol,and the treatment for 6 weeks. FT3,FT4,TSH in serum and BMD,Barthel index,pain index and the level of adverse events were compared after the treatment. Results FT3 and FT4 in serum decreased and TSH in serum increased（ P〈0. 05）,compared with control group,FT3,FT4 and TSH in serum of experimental group had no significant difference; BMD and Barthel index in 2 groups after the treatment were significantly increased,pain index decreased（ P〈0. 05）,compared with the control group,BMD and Barthel index in experimental group were higher（ P〈0. 05）. The adverse reaction rate of experimental group and control group had no significant difference.Conclusion Patients with hyperthyroidism treated with calcitriol has no effect on the level of thyroid hormone,but can improve hyperthyroidism osteoporosis related symptoms.
出处
《中国生化药物杂志》
CAS
2016年第3期85-87,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
2-巯基-1-甲基咪唑
骨化三醇
甲亢
临床疗效
2-mercapto-1-methyl imidazole
calcitriol
hyperthyroidism
clinical curative effect
